Built for the 25-bed hospital, not the 2,500-bed system.
Critical access hospitals are exempt from the GPO prohibition, subject to the orphan drug exclusion, and almost always run their 340B program with no dedicated staff. Enterprise vendors cannot serve them profitably. That is precisely why we do.
At a glance
- 01GPO prohibition
- Exempt
- 02Orphan drug exclusion
- Applies
- 03Typical 340B FTE
- 0
- 04Engagement model
- Fixed price
The specific position of a critical access hospital
Critical access hospitals were added to 340B eligibility later than disproportionate share hospitals, and they sit under a genuinely different rule set. Two differences matter most in practice.
The GPO prohibition does not apply. A CAH may continue purchasing covered outpatient drugs through a group purchasing organization, which removes the single highest-severity compliance risk that DSH hospitals carry. This is frequently misunderstood by advisors who work mainly with large hospitals.
The orphan drug exclusion does apply. Drugs designated for rare conditions are excluded from 340B pricing for CAHs, sole community hospitals, rural referral centers and free-standing cancer hospitals when used for the designated condition. Tracking this correctly requires attention that small teams rarely have spare.
The operational reality is that the pharmacy director is also the 340B program manager, the compliance lead and often the buyer. The program is real money for the hospital, and nobody has time to test it.
Small scope, fixed price, no scoping theatre
We do not run a two-week discovery process to price a single-site engagement at a 25-bed hospital. You should be able to get a number quickly and decide.
- Fixed-price single-site mock audit with a defined deliverable set
- Policy pack built from your actual workflow rather than a hospital template
- Orphan drug exclusion tracking review — routinely mishandled and rarely checked
- Fractional 340B program manager if you need named expertise without a hire
- Recertification readiness check ahead of your attestation window
- Remote delivery as standard, so you are not paying for travel
If a fixed-price mock audit is not the right starting point for your situation, we will say so rather than sell it.
The pharmacy director is already the whole program.
We scope around the reality that one person is running compliance, purchasing and oversight alongside three other jobs — not around a hospital compliance department that does not exist here.
Critical access hospitals — common questions
01Can we keep using our GPO?
Yes. The GPO prohibition does not apply to critical access hospitals, sole community hospitals or rural referral centers. This is one of the most common points of confusion when a CAH takes advice from a consultant whose experience is mainly with disproportionate share hospitals.
02What is the orphan drug exclusion and does it affect us?
Drugs with an orphan designation for a rare disease are excluded from 340B pricing for CAHs, SCHs, RRCs and free-standing cancer hospitals when used for that designated condition. It requires tracking designation status against actual use. It is frequently mishandled and rarely tested internally.
03Is 340B worth it for a hospital our size?
Usually yes, and the savings often fund a specific service the hospital would otherwise struggle to sustain. What is genuinely worth questioning is the number of contract pharmacy arrangements — small hospitals sometimes carry locations that generate almost no volume while creating real oversight obligation.
04We have nobody to run the remediation. Can you?
Yes. The fractional 340B program manager model exists for this situation — a named ACE-certified consultant for a defined number of hours each month, which is typically a fraction of the cost of a hire and available immediately.
Marked up with FAQPage schema for search and AI-answer eligibility.
Next step
A fixed price, quoted on the first call.
No discovery process to find out what a single-site mock audit costs at a 25-bed hospital.